Please login to the form below
CRISPR
This page shows the latest CRISPR news and features for those working in and with pharma, biotech and healthcare.
Cancer Research UK drives innovation with Cancer Research Horizons
Included in this is an end-to-end drug discovery offering from initial concept through to patient benefit, including CRISPR technologies, hit discovery methods and access to relevant disease models.
Latest news
-
Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn
Arbor is an early-stage life sciences company that 'uses its proprietary discovery engine to discover unique and wholly owned CRISPR-based genetic modifiers with differentiated genetic editing capabilities'. ... Under this deal, CRISPR received $900m
-
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
TDT, and the rapid progress that we and our partners at CRISPR have made toward registration and commercialisation,” he added. ... Along with Vertex/CRISPR Therapeutics, bluebird bio is also seeking to bring its gene therapy LentiGlobin for SCD (bb1111
-
Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology. ... The company’s platform is based on CRISPR technology (also known as CRISPR-Cas9) – CRISPRs are specialised stretches of DNA that can be cut by Cas9 enzymes.
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex is also looking to develop a CRISPR/Cas9 gene-editing therapy for the treatment of severe haemoglobinopathies in partnership with CRISPR therapeutics.
-
GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
The collaboration combines Vir Biotech’s monoclonal antibody platform technology with GSK’s expertise in functional genomics and capabilities in CRISPR screening to identify anti-coronavirus compounds.
More from news
Approximately 16 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
With the introduction of new data analytics capabilities and broader adoption in the pharmaceutical industry, research platforms that heavily depend on data (eg, RNAi and CRISPR therapies) will likely increase their
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Horizon Delivery is also an industry leader in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screenings, meaning they can identify key genes or genetic sequences that draw out specific functions of
-
Switzerland: a life sciences hub
cells engineered to display chimeric antigen receptors) and genome editing (ie, CRISPR/Cas, TALEN, ZNF).
-
25 Women Leaders in UK Healthcare (part 2)
Pioneers in the field include some notable women – such as CRISPR’s co-developers Jennifer Doudna and Emmanuelle Charpentier – although women remain in the minority in both the R&D and
-
The trials and tribulations of rare opportunities
In turn, this has allowed the generation of models for a variety of rare diseases, particularly monogenic diseases where tools such as CRISPR/ Cas9 have enabled the creation of cell- and
More from intelligence
Approximately 2 fully matching, plus 17 partially matching documents found.
Latest appointments
-
New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals
Lundberg most recently served as chief scientific officer of CRISPR Therapeutics, where he lead the development of the company’s first clinical trial application. ... Prior to CRISPR, he worked as head of translational medicine at Alexion
-
Former GSK CEO joins Synthego’s advisory board
Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach.
-
Marc Becker joins CRISPR Therapeutics
He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform. ... Becker said: “I am excited to join the CRISPR Therapeutics
-
CRISPR Therapeutics appoints Dr Tony Coles
Swiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors. ... Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track
More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Disrupting Cell Engineering with Non-Viral Modalities
Jessica Schwaber, Scientific Director, Cell &Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell &gene therapy commercial needs, current barriers to realizing the full potential of cell &gene
-
Creative Animodel
Creative Animodel is an experienced bioscience CRO，which would like to help you accelerate the process through preclinical services including transgenic animals, animal models of disease, CRISPR genome editing technology and
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- Scientists discover new approach to treat brain tumours
- Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure
- EIT Health and Biogen announce winners of first ‘neurotechprize’
- Assessing the value of interim analyses in clinical trials
- Taking a holistic approach to patient care
- Almirall and Evotec team up in multi-target dermatology alliance
- Moderna wins Prix Galien UK Award for best biotechnology product
- Why testing shouldn't be confined to the lab
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Live Webinar: Engaging Patients "Just-In-Time" with Machine Learning
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- Roche shares new positive Ocrevus data for MS patients
- How scientific storytelling can help Pharma cut through the noise
- Almirall and Evotec team up in multi-target dermatology alliance
- Christian Schade joins Aprea AB
- FDA approves Alexion’s Ultomiris for generalised myasthenia gravis
- First Herceptin biosimilar cleared in Europe
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
- Serious about sustainability?
- Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
